Generic drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg. The approved ...

In a meeting held with the principals of the four colleges, MVS Degree College, NTR College (Mahabubnagar), BRR College (Jadcherla), and Govt Degree College (Kodangal) , it was planned to first ...

Hyderabad: Aurobindo Pharma has announced that the United States Food and Drug Administration (USFDA) has issued 11 observations after an inspection at Raleigh Plant, North Carolina, USA, owned by ...

Aurobindo Pharma Limited announced on Friday that the United States Food and Drug Administration (US FDA) completed an inspection of its wholly-owned step-down subsidiary, Aurolife Pharma LLC's, ...

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received successful trial results for its new bone treatment medicine. The drug, called BP16, is a biosimilar of an existing ...

Intimation of completion of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned stepdown subsidiary of the Company.

The US Food and Drug Administration (USFDA) had conducted inspection at the plant from March 24, 2025, to April 10, 2025, Aurobindo Pharma said in a regulatory filing.

Large players with existing manufacturing facilities in the US, such as Piramal Pharma Ltd, Dr. Reddy's Laboratories Ltd, Sun Pharma and Aurobindo Pharma, are better insulated from tariffs even ...

Pharma stocks such as Sun Pharma, Aurobindo Pharma, Dr Reddy's Lab, Cipla, Gland Pharma, Zydus Lifesciences and Lupin would be in action on Friday after the US President Donald Trump halted ...

Aurobindo Pharma's Bone Treatment Drug Shows Promise in Tests Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has announced successful trial results for its new bone treatment medicine. The drug, ...

Firms like Dr Reddy's, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma and Gland Pharma reportedly earn anywhere from 30-50 per cent of their total revenues from the American market. Experts have ...

Gland Pharma topped the losses with a drop of almost 6 per cent, followed by Aurobindo Pharma, which fell by almost 5 per cent. Biocon's shares fell more than 4 per cent, and Sun Pharma, Lupin, Laurus ...